Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
145000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Who receives how much
Shares delivered during the applicable month: 145,000 shares (145,000 new shares; no treasury shares transferred)
EVO FUND (issued on 24 February 2026)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+2.40%Rate of increase
7,744,350 shares7,889,350Shares
Exercise ratio subject to the exercise restriction: 2.4%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
With exercise price adjustment clause. The exercise price during the applicable month ranged from ¥212 to ¥244. The adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total issued: 9,860; exercised during the applicable month: 1,450; unexercised at month-end: 5,500
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restriction was 2.4%.
Most recent equity financing
24 February 2026: Issuance, through a third-party allotment to EVO FUND, of new shares and the First Series of Stock Acquisition Rights (with exercise price adjustment clause). Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | Shares delivered during the applicable month: 145,000 shares (145,000 new shares; no treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 24 February 2026) |
| Dilution Rate | Exercise ratio subject to the exercise restriction: 2.4% |
| Total number of issued shares | 7,744,350 shares (as of the end of the month preceding the relevant month) → 7,889,350 shares (calculated as of the end of the applicable month) |
| Exercise price | With exercise price adjustment clause. The exercise price during the applicable month ranged from ¥212 to ¥244. The adjustment floor is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 9,860; exercised during the applicable month: 1,450; unexercised at month-end: 5,500 |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restriction was 2.4%. |
| Most recent equity financing | 24 February 2026: Issuance, through a third-party allotment to EVO FUND, of new shares and the First Series of Stock Acquisition Rights (with exercise price adjustment clause). Amount: Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these stock acquisition rights in May 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.